Genetic Rearrangements in Brain Tumors: A View from NTRK Article Swipe
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.5772/intechopen.1007388
· OA: W4408330893
There is growing interest in targeted therapies for oncological diseases, with neurotrophic tropomyosin receptor kinase (NTRK) genes emerging as promising targets in various solid tumors. The NTRK genes are essential for central nervous system (CNS) development and have been progressively recognized for their involvement in cancer development. This review explores the physiological role of NTRK genes in CNS development, their involvement in cancer development, and current evidence on the efficacy of NTRK inhibitors in treating CNS tumors. We highlight the prevalence of NTRK gene alterations in CNS tumors and explore the potential of NTRK inhibitors as a treatment option, focusing on recent discoveries and future directions. Additionally, we underscore the need for further research to improve NTRK fusion detection in CNS tumors, elucidate mechanisms of resistance to NTRK inhibitors, and conduct comprehensive clinical trials involving larger cohorts of patients with CNS tumors and brain metastases. This holistic approach, coupled with exploring the synergistic benefits of combining NTRK inhibitors with other therapeutic modalities, holds promise for advancing treatment outcomes in patients with CNS malignancies.
